Celgene Corp. has entered an agreement to acquire Delinia, Inc., a privately held biotechnology company developing therapeutics for autoimmune diseases, for $300 million upfront, and as much as an additional $475 million based on development, regulatory and commercial milestones. The transaction is expected to close 1Q17.   Celgene expands its inflammation and immunology pipeline with Delinia’s lead program, DEL106, as well as related second generation programs. DEL106 is an IL-2 mutein Fc fus...